Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
UNC Molecular Genetics Laboratory, |
RCV002294562 | SCV002587048 | uncertain significance | Kleefstra syndrome 2 | criteria provided, single submitter | research | ||
Ambry Genetics | RCV003101697 | SCV003567623 | uncertain significance | Inborn genetic diseases | 2021-08-10 | criteria provided, single submitter | clinical testing | The c.12674G>A (p.R4225Q) alteration is located in exon 51 (coding exon 51) of the KMT2C gene. This alteration results from a G to A substitution at nucleotide position 12674, causing the arginine (R) at amino acid position 4225 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Prevention |
RCV004534044 | SCV004716645 | uncertain significance | KMT2C-related disorder | 2024-01-29 | no assertion criteria provided | clinical testing | The KMT2C c.12674G>A variant is predicted to result in the amino acid substitution p.Arg4225Gln. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0018% of alleles in individuals of European (Non-Finnish) descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |